SCHEMBL7638728

SCHEMBL7638728

CC(C)(C)c1cc2ccccc2n1C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC10 Q969S8 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 2/20 0.36
ATM Q13315 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
DAO P14920 2/20 0.34
MCL1 Q07820 1/20 0.34
HPGD P15428 1/20 0.33
RECQL P46063 1/20 0.33
CDK4 P11802 2/20 0.32
CCND1 P24385 2/20 0.32
TP53 P04637 1/20 0.32
TERT O14746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22793157 0.82 HDAC10 (0.43) HDAC10HDAC6KMT2AKDM4EMEN1
SCHEMBL7756916 0.78 KDM4E (0.42) HDAC6KMT2AKDM4EMEN1CYP1A2
SCHEMBL30435050 0.78 KMT2A (0.50) HDAC10HDAC6KMT2AKDM4EMEN1
SCHEMBL10139087 0.78 KMT2A (0.50) HDAC10HDAC6KMT2AKDM4EMEN1
SCHEMBL16449989 0.77 KCNH2 (0.41) KMT2AMEN1CYP1A2CYP2C19ALDH1A1
SCHEMBL12827007 0.76 HDAC10 (0.40) HDAC10HDAC6KMT2AKDM4EMEN1
SCHEMBL26596972 0.76 KMT2A (0.36) KMT2AKDM4EMEN1CYP3A4ALDH1A1
SCHEMBL18511071 0.76 HDAC10 (0.40) HDAC10HDAC6KMT2AKDM4EMEN1
SCHEMBL13425019 0.74 ALDH1A1 (0.43) HDAC10HDAC6KMT2AKDM4EMEN1
SCHEMBL13483704 0.74 HDAC10 (0.40) HDAC10HDAC6KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 US disclosed
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 US disclosed
US-20240216526-A1 PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) 2024-07-04 US disclosed
US-20240216526-A1 PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) 2024-07-04 US disclosed
US-11584745-B2 Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2023-02-21 US disclosed
US-11584751-B1 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE (SHANGHAI) CO., LTD. (CN) 2023-02-21 US disclosed
US-20230051320-A1 TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME ECCOGENE INC. 2023-02-16 US disclosed
US-10988466-B2 Heterocyclic derivatives useful as SHP2 inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-04-27 US disclosed
US-20210032241-A1 AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2021-02-04 US disclosed
US-20200392128-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2020-12-17 US disclosed
US-20170369511-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2017-12-28 US disclosed
US-9708348-B2 Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-07-18 US disclosed
US-20160122365-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2016-05-05 US disclosed
US-7642272-B2 Cannabinoid receptor ligands SCHERING CORPORATION (US) 2010-01-05 US disclosed
US-6433112-B1 COORDINATION POLYMERIZATION CATALYST BAYER AKTIENGESELLSCHAFT (DE) 2002-08-13 US disclosed
EP-1042336-B1 PI-COMPLEX COMPOUNDS BAYER AG (DE) 2002-04-03 EP disclosed
EP-1042336-A1 PI-COMPLEX COMPOUNDS Bayer Aktiengesellschaft (DE) 2000-10-11 EP disclosed
WO-1999033852-A1 π-COMPLEX COMPOUNDS BAYER AKTIENGESELLSCHAFT (DE) 1999-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584751-B1 Substituted imidazoles as GLP-1 receptor agonists GLP1R, GIPR, SLC5A1 HDAC10 2387/4885HDAC6 871/4885KMT2A 3521/4885
US-20230051320-A1 TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME GLP1R, SLC5A1, GIPR HDAC10 1852/4885HDAC6 1622/4885KMT2A 4586/4885
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists GLP1R, GIPR, SLC5A1 HDAC10 2387/4885HDAC6 871/4885KMT2A 3521/4885
US-20170369511-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB HDAC10 614/4885HDAC6 340/4885KMT2A 3819/4885
US-20210032241-A1 AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF ALK, NOTUM, WEE1 HDAC10 2349/4885HDAC6 3441/4885KMT2A 2636/4885
US-10988466-B2 Heterocyclic derivatives useful as SHP2 inhibitors PTPRJ, PTPN5, PTPN1 HDAC10 1220/4885HDAC6 683/4885KMT2A 1201/4885
US-20160122365-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB HDAC10 614/4885HDAC6 340/4885KMT2A 3819/4885
US-20200392128-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS PTPN5, PTPN1, PTPRJ HDAC10 1242/4885HDAC6 665/4885KMT2A 1120/4885
US-20240216526-A1 PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF SKP1, ADCY7, ERBB2 HDAC10 4456/4885HDAC6 355/4885KMT2A 1387/4885
US-11584745-B2 Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof ALK, NOTUM, WEE1 HDAC10 2349/4885HDAC6 3441/4885KMT2A 2636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.